logo
ENTITY
Astellas Pharma

Astellas Pharma (4503 JP)

133
Analysis
Health Care • Japan
Astellas Pharma Inc. is a pharmaceutical company committed to the therapeutic fields of Urology, Immunology including Transplantation and Infectious Diseases, Oncology, Neuroscience and DM Complications and Metabolic Diseases. With over 17,000 global employees, Astellas researches, develops, manufactures, and promotes its prescription drugs through subsidiaries in the US, Europe, and Asia
more
bullish•Thematic (Sector/Industry)
•24 Apr 2018 22:17

Japan Pharma - FY17e Earnings Preview (I)

Astellas Pharma Inc (4503 JP) - April 26, 2018FY18e potential guidance  Moderate Xtandi and Tarceva growth and Vesicare US patent expiry led y-o-y...

Logo
Share
bullish•MSCI ACWI Index
•10 Apr 2018 23:02

Global Equity Strategy: Opportunities in Japan, HK, &  EM

In our April International Strategy, we explore the recent consolidation across global equity markets and examine the following opportunities...

Logo
Vermilion Research
194 Views
Share
bullish•Takeda Pharmaceutical
•29 Mar 2018 14:03

Japan Pharmaceutical - Sector Overview

Core coverage – relative valuations Takeda Pharmaceutical Co Ltd (4502 JP) (NB: Pre-Shire announcement | Pro-Forma analysis to be published...

Logo
Share
bearish•Fast Retailing
•12 Feb 2018 08:14

Trading the BOJ-Nikkei 225 Baskets

One week ago in The BOJ's Ongoing ETF Impact - Is a Nikkei 225 Reshuffle in the Cards? I discussed the BOJ's past and current ETF purchasing...

Logo
Travis Lundy
469 Views
Share
bearish•Fast Retailing
•04 Feb 2018 14:29

The BOJ's Ongoing ETF Impact - Is a Nikkei 225 Reshuffle in the Cards?

Just over six months ago, a breathless article on Bloomberg noted that according to their calculations, the BOJ owned 71% of the ETFs in the...

Logo
Travis Lundy
1.6k Views
Share

Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.40.5

x